Advanced

Immune tolerance induction: recombinant vs. human-derived product

Berntorp, Erik LU (2001) In Haemophilia 7(1). p.109-113
Abstract
The ultimate goal in the treatment of high-responding inhibitors in congenital haemophilia is to induce immune tolerance (IT). Since the advent of highly purified factor VIII products, especially recombinant ones, the issue has been raised of whether the type of product has an impact on treatment success. It is clear that IT induction is possible to achieve with both recombinant products and human-derived products, but there is a lack of comparative studies. Different theoretical aspects indicate that human-derived concentrate, especially of low purity, and with a high content of von Willebrand factor, may have a better tolerizing effect.
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haemophilia
volume
7
issue
1
pages
109 - 113
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • pmid:11136391
  • scopus:0035133958
ISSN
1351-8216
DOI
10.1046/j.1365-2516.2001.00466.x
language
English
LU publication?
yes
id
d98ef86e-e193-4a5a-a14d-fcf94bd947cb (old id 1121720)
date added to LUP
2008-06-25 09:22:23
date last changed
2018-01-07 05:28:05
@article{d98ef86e-e193-4a5a-a14d-fcf94bd947cb,
  abstract     = {The ultimate goal in the treatment of high-responding inhibitors in congenital haemophilia is to induce immune tolerance (IT). Since the advent of highly purified factor VIII products, especially recombinant ones, the issue has been raised of whether the type of product has an impact on treatment success. It is clear that IT induction is possible to achieve with both recombinant products and human-derived products, but there is a lack of comparative studies. Different theoretical aspects indicate that human-derived concentrate, especially of low purity, and with a high content of von Willebrand factor, may have a better tolerizing effect.},
  author       = {Berntorp, Erik},
  issn         = {1351-8216},
  language     = {eng},
  number       = {1},
  pages        = {109--113},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {Immune tolerance induction: recombinant vs. human-derived product},
  url          = {http://dx.doi.org/10.1046/j.1365-2516.2001.00466.x},
  volume       = {7},
  year         = {2001},
}